Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women

NCT01300351 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

249

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Fulvestrant
DRUG: Placebo

Sponsor

AstraZeneca